Scientific Sessions 2024  /  Redefining Arrhythmia Treatment: Pushing Boundaries  /  Discussant: BRAIN AF
Logo

American Heart Association

  138
  0

Final ID:

Discussant: BRAIN AF

  • Hankey, Graeme  ( UNIVERSITY WESTERN AUSTRALIA , Perth , Western Australia , Australia )
  • Hylek, Elaine  ( BOSTON UNIVERSITY , Boston , Massachusetts , United States )
  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
    • Author Disclosures:
    Graeme Hankey: No Answer | Elaine Hylek: No Answer | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Redefining Arrhythmia Treatment: Pushing Boundaries

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
Discussant: VANISH2

Tedrow Usha

Evolution of Care of Patients with Arrhythmia

Prystowsky Eric

More abstracts from these authors:
Atrial Cardiopathy and Cryptogenic Stroke

Kamel Hooman

The Trouble with ESUS: What do the studies tell us? Where do we do from here?

Kamel Hooman, Messe Steven

You have to be authorized to contact abstract author. Please, Login
Not Available